Benzinga | May 6, 2021 06:23AM EDT

Evercore ISI Group Upgrades Ultragenyx Pharmaceutical to Outperform, Announces $144 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from In-Line to Outperform and announces $144 price target.